MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage ...

MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports. The Financial ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

MSD's booth is seen during an expo in Shanghai in November. [PHOTO/CHINA DAILY] With a long-term commitment to the Chinese market, United States-based global pharmaceutical company MSD plans to ...

Architectural schematic representation of the proposed CADiST, wherein the DsiFormer effectuates explicit modeling of spatial continuity between adjacent image slices via dual-level hierarchical ...